SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics priced an upsized public offering of 7,313,582…

Dianthus Therapeutics, Inc. · PRESS-RELEASE filed Mar 10, 2026 at 22:54 ET

At the news

NEUTRALIMPACT 6/10

PRESS-RELEASE filed Mar 10, 2026 at 22:54 ET

Dianthus Therapeutics priced an upsized public offering of 7,313,582 shares at $81.00 per share and pre-funded warrants for 402,468 additional shares at $80.999, raising approximately $625 million in gross proceeds. The funds will support clinical development, commercial readiness, and general corporate purposes, with a 30-day underwriter option to purchase up to an additional 1,157,407 shares.

  • Priced public offering of 7,313,582 common shares at $81.00 per share
  • Pre-funded warrants issued for 402,468 shares at $80.999, exercisable immediately at $0.001 per share
  • Total gross proceeds: ~$625 million (before expenses)
  • Underwriters granted 30-day option to purchase up to 1,157,407 additional shares

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access